Eybna Technologies

Company Overview

Snapshot

Founded in October 2014 by Nadav Eyal, Eybna Technologies operates with 51–200 employees. The company is a technology firm and terpene manufacturer, focusing on the therapeutic benefits of cannabis phytochemicals. In November 2021, Eybna Technologies established a cooperation with Gat Foods (IBBL) to develop a new category of functional beverages.

Business overview

Eybna Technologies is a technology company and terpene manufacturer specializing in the research and development of cannabis phytochemicals, particularly terpenes, for therapeutic applications. The company develops receptor-specific formulations aimed at wellness needs such as focus, sleep, anxiety, pain, inflammation, and mood management. Eybna serves the health tech, life sciences, pharmaceutical, and biotechnology sectors, with a focus on integrating advanced research into product development for the cannabis, food and beverage, and wellness industries.

Strategic signal

In November 2021, Eybna Technologies partnered with Gat Foods (IBBL) to develop functional beverages using terpene formulations. This collaboration signals Eybna's strategic expansion beyond traditional cannabis applications into the broader functional beverage market, which is projected to reach $198 billion by 2026. For investors, this indicates a move towards diversifying revenue streams and leveraging their terpene expertise in a rapidly growing consumer market, validating the commercial potential of their research.

Company Intelligence Q&A

What was a significant product launch by Eybna Technologies?

In October 2021, Eybna Technologies launched its. This line features 10 Receptor-Specific terpene and cannabinoid proprietary formulations.

What strategic partnership did Eybna Technologies form in the functional beverage sector?

In November 2021, Eybna Technologies established a cooperation with Gat Foods (IBBL), part of the CBC group, to develop a new category of functional beverages using terpene formulations. This partnership began with a commercial pilot in Israel and is intended to expand internationally.

What research did Eybna Technologies conduct regarding COVID-19?

In June 2022, Eybna Technologies announced discoveries in the study of terpenes and cannabinoids, including a cannabinoid formulation in 2020 that effectively blocked the novel coronavirus from penetrating living cells. The company is conducting clinical studies on this formulation as a potential COVID-19 treatment.

What was the focus of Eybna Technologies' collaboration with CannaSoul Analytics?

In April 2020, Eybna Technologies collaborated with CannaSoul Analytics to develop a proprietary terpene formulation for treating viral infections, specifically focusing on COVID-19, by modulating cytokine storms. The collaboration aimed to optimize Eybna's NT-VRL™ terpene formulation for its anti-inflammatory and anti-viral properties.

What is Eybna Technologies' core area of research and product development?

Eybna Technologies specializes in terpene research and manufacturing. The company focuses on utilizing the therapeutic benefits of cannabis phytochemicals to develop receptor-specific formulations for various wellness applications, aiming for predictable cannabis consumption and broader health benefits.